Investors

Press Releases

Press Releases

Press Releases

April 7, 2020
Collegium to Participate in Upcoming Investor Conference
STOUGHTON, Mass. , April 07, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will participate in the following investor conference in April: The
February 27, 2020
Collegium Reports Full-Year 2019 Revenue of $296.7 Million
– 2019 Revenue Growth of 6%, Driven by Xtampza ER revenue growth of 51% – – Xtampza ® ER Prescriptions Grew 49% in 2019 – – Collegium Guides to Profitability in 2020 – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass. , Feb. 27, 2020 (GLOBE NEWSWIRE) --   Collegium
February 13, 2020
Collegium Announces Closing of the Nucynta Franchise Acquisition
– Collegium Announces Closing of Convertible Senior Notes Offering and Exercise in Full of Over-Allotment Option – – Collegium will Host Conference Call to Discuss Fourth Quarter 2019 Financial Results and Provide Corporate Update – STOUGHTON, Mass. , Feb.
February 6, 2020
Collegium to Acquire U.S. Rights to Nucynta Franchise
– Financially Transformative Acquisition – – Expected to Significantly Grow Net Income, EBITDA and Operating Cash Flows – – Structure of the Financing Allows for Rapid De-Leveraging – – Provides Financial Flexibility to Pursue Future Business Development Transactions – STOUGHTON, Mass. , Feb.
January 7, 2020
Collegium Provides 2020 Financial Guidance
– Xtampza ® ER Revenues Expected in the Range of $150.0 Million to $160.0 Million for 2020 – STOUGHTON, Mass. , Jan. 07, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today